Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $62 Price Target
Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $62 Price Target
查爾丹資本維持對Rocket Pharmaceuticals的買入評級，維持62美元的目標價格。
Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $62 price target.
Chardan Capital分析師Geulah Livshits認爲Rocket Pharmaceuticals（納斯達克：RCKT）爲買入，目標價爲62美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。